Table 1: Base-case cost-effectiveness results.
Intervention | Cost, $ | No. of life-years | No. of QALYs | Incremental $/life-year gained | Incremental $/QALY gained |
---|---|---|---|---|---|
PIAAF-Pharmacy screening | 443.99 | 9.027 | 6.880 | ||
No screening | 417.93 | 9.023 | 6.876 | ||
Incremental | 26.06 | 0.0032 | 0.0035 | 8213 | 7480 |
Note: PIAAF-Pharmacy = Program for the Identification of 'Actionable' Atrial Fibrillation in the Pharmacy Setting, QALY = quality-adjusted life-year.